Since 2012, the FDA has approved Xeljanz for several uses:
2012: Xeljanz for rheumatoid arthritis
2017: Xeljanz and Xeljanz XR for psoriatic arthritis
2018: Xeljanz for ulcerative colitis
2020: Xeljanz for polyarticular juvenile idiopathic arthritis